by John R. Fischer
, Senior Reporter | April 24, 2018
Royal Philips is integrating its Pinnacle3 16.2 Auto-Planning solution with Sun Nuclear’s PlanIQ Software to help radiation oncologists plan and meet feasible treatment objectives.
The Dutch-based healthcare giant announced the joint collaboration this weekend at the ESTRO 37th Annual Meeting in Barcelona, Spain as it showcased its integrated radiation oncology solutions to attendees.
“As a leader in radiation oncology quality assurance, Sun Nuclear has developed a technology in PlanIQ that can determine, based on the patient’s anatomy and location of the tumor, the lower limits of radiation that could be feasibly achieved for that patient’s treatment,” Todd Deterding, marketing director of radiation oncology solutions at Philips, told HCB News. “This information easily integrates into our Pinnacle3 system to provide the best possible starting place for Auto-Planning in order to begin the process of creating a high-quality plan.”
Radiation oncologists often struggle in establishing personalized treatment planning goals that limit healthy tissue’s exposure to radiation based on each patient’s anatomy, and doing so consistently across their patient volume.
PlanIQ uses unique and patented technology to construct reachable, patient-specific goals for clinicians based on the individual anatomy of each patient.
Pinnacle3 16.2 with Auto-Planning is equipped with advanced automated tools for reducing the total time required to create IMRT or VMAT plans.
The solution aids clinicians in making effective decisions when changes occur in patient anatomy and dose exposure, and is currently utilized by the Rutherford Cancer Centre in South Wales, the first to offer
proton therapy in the U.K.
“Pinnacle3 Auto-Planning, together with PlanIQ, helps to minimize the exposure of healthy tissues, further reducing the risk of toxicities to sensitive, healthy tissues, thus allowing the patient the opportunity to better tolerate the course of treatment and lower the costs of care for the clinic,” said Deterding.
Philips also displayed its iPatient for Big Bore CT solution, which provides a patient-centered imaging workflow for consistent image quality from one scan to the next across diverse patient populations; its IQON Spectral CT Elite which offers
greater diagnostic certainly through its enhanced tumor characterization features; its Ingenia MR-RT platform with a commercial MR-only simulation package which can be used to address general pelvic soft-tissue cancers, including rectal, bladder, gynecological and prostate; and its IntelliSpace Portal 10, an advanced visualization and analysis solution that offers a comprehensive clinical review while reducing variance in analysis.
In addition, the enterprise also showcased the MR-linac system of its technology partner, Elekta. The system is the only one that integrates an advanced linear accelerator and high-field, 1.5 Tesla MR imaging without damaging either technology.
The use of its MR simulation package in the MR-linac demonstrates the many similarities that exist between the solution and Philips’ Ingenia MR-RT, while providing consistent workflows and image quality from MR simulation through online MR guidance during radiotherapy.